A Phase 2a, double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 when added to standard of care (SoC) versus standard of care alone in subjects with advanced solid tumors (BOLSTER)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503740-14-00

Acronym

LSTA1-P02

Enrollment

Registered

2023-08-14

Start date

Unknown

Completion date

2024-03-15

Last updated

2024-02-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and neck cancer, Cholangiocarcinoma

Brief summary

Incidence and severity of adverse events

Detailed description

overall survival, progression free survival, Objective response rate, Duration of response

Interventions

DRUGGEMCITABINE

DRUGDURVALUMAB

DRUGLSTA1

DRUGCISPLATIN

DRUGPlacebo

DRUGPACLITAXEL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence and severity of adverse events	—

Secondary

Measure	Time frame
overall survival, progression free survival, Objective response rate, Duration of response	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026